Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Radial Approach, 1st choice in Acute Coronary Syndromes

Original title: Radial Versus Femoral Randomized Investigation in ST-Segment Elevation Acute Coronary síndrome. The RIFLE-STEACS (Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome) Study. Reference: Enrico Romagnoli et al. J Am Coll Cardiol 2012;60:2481–9.

Bleeding in patients with acute coronary syndromes (ACS) is an independent predictor of morbidity and mortality. Until today, evidence supporting the radial approach came from studies not strong enough to show significant difference in hard clinical end points.

This multicenter study included 1001 patients with ST segment elevation ACS randomized 1:1, radial vs. femoral. All patients were positive for Allen’s tested in both hands and operators were required that at least a 50% of performed angioplasty procedures by radial approach.

Primary end point was a composite between cardiac death, infarction, stroke, revascularization and non surgical bleeding, Baseline characteristics were well balanced, around 10% were in Killip class III/IV, and 8%required intra-aortic balloon counterpulsation. There were no differences in symptom/balloon time and door/balloon time between the groups. The overall rate of vascular approach crossover was 6.1%.

The primary end point was significantly lower in the radial group compared to the femoral (13.6% vs. 21% p=0.003). Cardiac death was also significantly lower in the radial group (5.2% vs. 9.2% p=0.02) and there were no differences in infarction (1.2% vs. 1.4% p=1), revascularization (1.2% vs. 1.8% p=0.6) or stroke occurrence (0.8% vs. 0.6% p=0.72).

Bleeding occurred in 10% of procedures and was lower in the radial group (7.8% vs. 12.2% p=0.026); this difference was due to a reduction of 60% in bleeding associated to access site. Non surgical bleeding was 53% of all bleeding and was similar in both groups (5.2% vs. 5.4% p=1).

Using TIMI criteria, no differences were observed in major bleeding but differences were noted in minor bleeding (radial 4% vs. femoral 7.2% p=0.038). Hospitalization was also significantly lower for those accessed by radial approach.

Conclusion 

The RIFLE-STEACS trial clearly shows the advantages of the radial approach vs. the femoral approach in patients with ST segment elevation ACS.

Editorial Comment:

This is the first study with enough statistical strength to show different in hard clinical end points to make the radial approach the number one choice, also in the emergency room. The low frequency use of Bivalirudin (a mere 8%, a more frequent use may reduce the gap in terms of bleeding), and operator training were study limitations.

Though the radial approach significantly reduces bleeding and mortality, bleeding events not associated with access sites are still 53%. We should use the radial approach but also assess patients with bleeding risk scores (e.g. CRUSADE) to adjust antiplatelet and antithrombotics on a case by case basis. 

SOLACI.ORG

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...